| review article | Q7318358 |
| scholarly article | Q13442814 |
| P2093 | author name string | Ulrich W Preuss | |
| Udo Bonnet | |||
| P2860 | cites work | Withdrawal seizures seen in the setting of synthetic cannabinoid abuse | Q87022907 |
| Cannabinoid hyperemesis syndrome | Q87221088 | ||
| Rapid Changes in CB1 Receptor Availability in Cannabis Dependent Males after Abstinence from Cannabis | Q87255327 | ||
| Abstinence symptoms following smoked marijuana in humans | Q48769083 | ||
| Functioning of cannabis abuse and dependence criteria across two different countries: the United States and The Netherlands | Q50615468 | ||
| Considering gender in cannabinoid research: a step towards personalized treatment of marijuana addicts | Q50790649 | ||
| Abstinence phenomena of chronic cannabis-addicts prospectively monitored during controlled inpatient detoxification: cannabis withdrawal syndrome and its correlation with delta-9-tetrahydrocannabinol and -metabolites in serum | Q51055346 | ||
| Prospective assessment of cannabis withdrawal in adolescents with cannabis dependence: a pilot study. | Q51895311 | ||
| Cannabis dependence, withdrawal, and reinforcing effects among adolescents with conduct symptoms and substance use disorders. | Q52187770 | ||
| An evaluation of the history of a marijuana withdrawal syndrome in a large population. | Q52274587 | ||
| [Frequent non-medical cannabis use: health sequelae and effectiveness of detoxification treatment]. | Q52308521 | ||
| The therapeutic use of cannabinoids: Forensic aspects. | Q53742574 | ||
| Marihuana withdrawal symptoms | Q70524947 | ||
| Marijuana withdrawal among adults seeking treatment for marijuana dependence | Q73312718 | ||
| Withdrawal symptoms in cannabis indica addicts | Q80611472 | ||
| [Cannabis hyperemesis syndrome] | Q84405968 | ||
| Early withdrawal effects in a heavy cannabis smoker during hemodialysis | Q86099334 | ||
| Synthetic cannabinoid withdrawal: a new demand on detoxification services | Q86529767 | ||
| Posttraumatic stress disorder and cannabis use characteristics among military veterans with cannabis dependence | Q42596561 | ||
| Cannabis withdrawal severity and short-term course among cannabis-dependent adolescent and young adult inpatients | Q43270705 | ||
| The cannabis experiment | Q43425209 | ||
| Characteristics of DSM-IV and ICD-10 cannabis dependence among Australian adults: results from the National Survey of Mental Health and Wellbeing | Q43453410 | ||
| Cannabis withdrawal syndrome: An important diagnostic consideration in adolescents presenting with disordered eating | Q43756797 | ||
| Suspected dronabinol withdrawal in an elderly cannabis-naive medically ill patient | Q44980517 | ||
| Psychometric evaluation of the Customary Drinking and Drug Use Record (CDDR): a measure of adolescent alcohol and drug involvement | Q46085791 | ||
| Withdrawal symptoms do not predict relapse among subjects treated for cannabis dependence | Q46866973 | ||
| Long-term Effects of Maternal Deprivation on the Volume, Number and Size of Neurons in the Amygdala and Nucleus Accumbens of Rats | Q47272068 | ||
| Changes in cigarette and alcohol use during cannabis abstinence. | Q48120865 | ||
| Cannabidiol for the treatment of cannabis withdrawal syndrome: a case report | Q48216300 | ||
| Does Cannabidiol Protect Against Adverse Psychological Effects of THC? | Q21129107 | ||
| The global epidemiology and contribution of cannabis use and dependence to the global burden of disease: results from the GBD 2010 study | Q21132482 | ||
| Smoking tobacco along with marijuana increases symptoms of cannabis dependence | Q24650310 | ||
| Cannabinoid hyperemesis: cyclical hyperemesis in association with chronic cannabis abuse | Q24685807 | ||
| Progress toward pharmacotherapies for cannabis-use disorder: an evidence-based review | Q26746192 | ||
| Adverse Effects of Synthetic Cannabinoids: Management of Acute Toxicity and Withdrawal | Q26748662 | ||
| The Role of Cannabinoids in Neuroanatomic Alterations in Cannabis Users | Q26768135 | ||
| Physiology and neurobiology of stress and adaptation: central role of the brain | Q28235550 | ||
| Aerobic exercise training reduces cannabis craving and use in non-treatment seeking cannabis-dependent adults | Q28477355 | ||
| Risks associated with the non-medicinal use of cannabis | Q30316580 | ||
| Cannabis withdrawal in chronic, frequent cannabis smokers during sustained abstinence within a closed residential environment | Q30576095 | ||
| Seizure exacerbation in two patients with focal epilepsy following marijuana cessation | Q30577728 | ||
| Toxicity with Intravenous Injection of Crude Marijuana Extract | Q33486046 | ||
| Cannabis dependence in the San Francisco Family Study: age of onset of use, DSM-IV symptoms, withdrawal, and heritability | Q33585794 | ||
| Amygdala reactivity is inversely related to level of cannabis use in individuals with comorbid cannabis dependence and major depression | Q33738017 | ||
| The clinical global impressions scale: applying a research tool in clinical practice | Q33894649 | ||
| Abstinence symptoms during withdrawal from chronic marijuana use. | Q33928980 | ||
| Marijuana abstinence effects in marijuana smokers maintained in their home environment | Q33954914 | ||
| The time course and significance of cannabis withdrawal | Q33967997 | ||
| Cannabis withdrawal in patients with and without opioid dependence | Q34021894 | ||
| Cannabis withdrawal symptoms in non-treatment-seeking adult cannabis smokers | Q34091534 | ||
| Reversible and regionally selective downregulation of brain cannabinoid CB1 receptors in chronic daily cannabis smokers | Q34199610 | ||
| Nabilone therapy for cannabis withdrawal presenting as protracted nausea and vomiting | Q34235592 | ||
| The prevalence of cannabis withdrawal and its influence on adolescents' treatment response and outcomes: a 12-month prospective investigation | Q34252749 | ||
| Neural mechanisms for the cannabinoid modulation of cognition and affect in man: a critical review of neuroimaging studies | Q34310759 | ||
| Moving around the molecule: relationship between chemical structure and in vivo activity of synthetic cannabinoids. | Q34373631 | ||
| Quantifying the clinical significance of cannabis withdrawal | Q34437940 | ||
| Potency trends of Δ9-tetrahydrocannabinol, cannabidiol and cannabinol in cannabis in the Netherlands: 2005-15. | Q34487906 | ||
| Proportion of patients in south London with first-episode psychosis attributable to use of high potency cannabis: a case-control study | Q34493623 | ||
| Open-label pilot study of quetiapine treatment for cannabis dependence | Q34512547 | ||
| Therapeutic Potential of Cannabinoids in Psychosis. | Q34512679 | ||
| Drug vaping applied to cannabis: Is "Cannavaping" a therapeutic alternative to marijuana? | Q34528377 | ||
| Do withdrawal-like symptoms mediate increased marijuana smoking in individuals treated with venlafaxine-XR? | Q34615910 | ||
| Analysis of cannabis seizures in NSW, Australia: cannabis potency and cannabinoid profile | Q34875298 | ||
| Sleep disturbance and the effects of extended-release zolpidem during cannabis withdrawal | Q35058880 | ||
| Cannabis Withdrawal Among Detained Adolescents: Exploring the Impact of Nicotine and Race | Q35090810 | ||
| Cannabis withdrawal in adolescent treatment seekers | Q35112935 | ||
| Comparison of cannabis and tobacco withdrawal: severity and contribution to relapse | Q35133776 | ||
| Dronabinol for the treatment of cannabis dependence: a randomized, double-blind, placebo-controlled trial | Q35160234 | ||
| Role of the endogenous cannabinoid system in nicotine addiction: novel insights | Q35216481 | ||
| Cannabis withdrawal predicts severity of cannabis involvement at 1-year follow-up among treated adolescents. | Q35623063 | ||
| Diagnostic criteria for cannabis withdrawal syndrome | Q35850737 | ||
| Effects of baclofen and mirtazapine on a laboratory model of marijuana withdrawal and relapse | Q35881015 | ||
| Investigation of sex-dependent effects of cannabis in daily cannabis smokers | Q35898817 | ||
| Review of the validity and significance of cannabis withdrawal syndrome | Q35932862 | ||
| A proof-of-concept randomized controlled study of gabapentin: effects on cannabis use, withdrawal and executive function deficits in cannabis-dependent adults | Q35982249 | ||
| Effects of THC and lofexidine in a human laboratory model of marijuana withdrawal and relapse | Q36024183 | ||
| Craving is associated with amygdala volumes in adolescent marijuana users during abstinence | Q36054658 | ||
| Naltrexone Maintenance Decreases Cannabis Self-Administration and Subjective Effects in Daily Cannabis Smokers. | Q36059911 | ||
| The co-occurring use and misuse of cannabis and tobacco: a review | Q36097783 | ||
| A double-blind randomized controlled trial of N-acetylcysteine in cannabis-dependent adolescents. | Q36137192 | ||
| Examining the profile of high-potency cannabis and its association with severity of cannabis dependence. | Q36178411 | ||
| A human laboratory study investigating the effects of quetiapine on marijuana withdrawal and relapse in daily marijuana smokers | Q36301495 | ||
| Roles for the endocannabinoid system in ethanol-motivated behavior. | Q36373102 | ||
| A within-subject comparison of withdrawal symptoms during abstinence from cannabis, tobacco, and both substances | Q36406999 | ||
| Receptor-independent actions of cannabinoids on cell membranes: focus on endocannabinoids | Q36439301 | ||
| The cannabis withdrawal syndrome | Q36448206 | ||
| Predictors of marijuana relapse in the human laboratory: robust impact of tobacco cigarette smoking status | Q36468008 | ||
| Sex differences in cannabis withdrawal symptoms among treatment-seeking cannabis users | Q36562406 | ||
| Cannabis Withdrawal, Posttreatment Abstinence, and Days to First Cannabis Use Among Emerging Adults in Substance Use Treatment: A Prospective Study | Q36567126 | ||
| Cannabis withdrawal is common among treatment-seeking adolescents with cannabis dependence and major depression, and is associated with rapid relapse to dependence | Q36932053 | ||
| Effects of fixed or self-titrated dosages of Sativex on cannabis withdrawal and cravings. | Q36932158 | ||
| Pharmacological and psychosocial interventions for cannabis use disorders | Q36948826 | ||
| Antagonist-elicited cannabis withdrawal in humans | Q37029517 | ||
| A genetic perspective on the proposed inclusion of cannabis withdrawal in DSM-5. | Q37070118 | ||
| fMRI study of neural sensitization to hedonic stimuli in long-term, daily cannabis users | Q37235385 | ||
| Relief of cannabis withdrawal symptoms and cannabis quitting strategies in people with schizophrenia | Q37244113 | ||
| Prevalence of Marijuana Use Disorders in the United States Between 2001-2002 and 2012-2013. | Q37285983 | ||
| Gap Junction Blockers: An Overview of their Effects on Induced Seizures in Animal Models. | Q37310526 | ||
| Cannabis withdrawal in the United States: results from NESARC. | Q37421751 | ||
| Effects of zolpidem alone and in combination with nabilone on cannabis withdrawal and a laboratory model of relapse in cannabis users | Q37635636 | ||
| Novel Pharmacologic Approaches to Treating Cannabis Use Disorder | Q38222436 | ||
| A review of co-morbid tobacco and cannabis use disorders: possible mechanisms to explain high rates of co-use | Q38348213 | ||
| Cannabinoid replacement therapy (CRT): Nabiximols (Sativex) as a novel treatment for cannabis withdrawal. | Q38380396 | ||
| A new method of cannabis ingestion: the dangers of dabs? | Q38417091 | ||
| Nabiximols as an agonist replacement therapy during cannabis withdrawal: a randomized clinical trial. | Q38437649 | ||
| Substance use modulates stress reactivity: Behavioral and physiological outcomes | Q38747433 | ||
| From Phytocannabinoids to Cannabinoid Receptors and Endocannabinoids: Pleiotropic Physiological and Pathological Roles Through Complex Pharmacology | Q38821074 | ||
| Is there evidence for symptoms of cannabis withdrawal in the national epidemiologic survey of alcohol and related conditions? | Q39320118 | ||
| Cannabis withdrawal among non-treatment-seeking adult cannabis users | Q39355645 | ||
| The Cannabis Withdrawal Scale development: patterns and predictors of cannabis withdrawal and distress | Q39732890 | ||
| Cannabis and its Problems | Q39931377 | ||
| Abrupt Quitting of Long-term Heavy Recreational Cannabis Use is Not Followed by Significant Changes in Blood Pressure and Heart Rate | Q40113994 | ||
| Relating blood concentrations of tetrahydrocannabinol and metabolites to pharmacologic effects and time of marijuana usage. | Q40721635 | ||
| Age at first use and later substance use disorder: Shared genetic and environmental pathways for nicotine, alcohol, and cannabis | Q41644896 | ||
| P275 | copyright license | Creative Commons Attribution-NonCommercial 3.0 Unported | Q18810331 |
| P6216 | copyright status | copyrighted | Q50423863 |
| P304 | page(s) | 9-37 | |
| P577 | publication date | 2017-04-27 | |
| P1433 | published in | Substance Abuse and Rehabilitation | Q15817526 |
| P1476 | title | The cannabis withdrawal syndrome: current insights | |
| P478 | volume | 8 |
| Q89611766 | Abrupt withdrawal of cannabidiol (CBD): A randomized trial |
| Q90533701 | Cognitive and Mental Health Predictors of Withdrawal Severity During an Active Attempt to Cut Down Cannabis Use |
| Q90654970 | Correlates and Potential Confounds of Cannabis Withdrawal Among High-Risk Adolescents |
| Q58552712 | DSM-5 cannabis withdrawal syndrome: Demographic and clinical correlates in U.S. adults |
| Q99585315 | Dependence, withdrawal and rebound of CNS drugs: an update and regulatory considerations for new drugs development |
| Q94461684 | Long-Term Aberrations To Cerebellar Endocannabinoids Induced By Early-Life Stress |
| Q58102489 | Medical Use of Cannabinoids |
| Q48287156 | Methods to reduce false reporting of substance abstinence in clinical research. |
| Q60640862 | Pharmacological properties of cannabidiol in the treatment of psychiatric disorders: a critical overview |
| Q47963315 | The Current State of Pharmacological Treatments for Cannabis Use Disorder and Withdrawal |
| Q60937774 | Theoretical Explanation for Reduced Body Mass Index and Obesity Rates in Cannabis Users |
Search more.